ClinConnect ClinConnect Logo
Search / Trial NCT06390969

TBP Survey Among Respiratory Physicians

Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 26, 2024

Trial Information

Current as of July 23, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

Tuberculosis (TB) is one of the major global health threats, with an estimated 10.6 million people infected with TB in 2021, with 1.6 million dying from the disease. Apart from pulmonary involvement as the major manifestation of TB, there is an increasing trend of extrapulmonary TB (EPTB) reported in different continents. Among EPTB, TB pleuritis (TBP) was the most prevalent form in several large Chinese retrospective studies.

Diagnosing TBP is challenging due to paucibacillary involvement (TB disease caused by a small number of bacteria) of the pleural space. A diagnosis of definite TBP c...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Respiratory doctors practising in Asia-Pacific region
  • Exclusion Criteria:
  • Do not consent for the study

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

Hong Kong, , Hong Kong

Patients applied

0 patients applied

Trial Officials

David SC Hui, MD

Study Director

Chinese University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported